Rationale and Design of EMPOWER, a Pragmatic Randomized Trial of Automated Hovering in Patients With Congestive Heart Failure

被引:10
|
作者
Mehta, Shivan J. [1 ,2 ,3 ]
Volpp, Kevin G. [1 ,2 ,3 ]
Asch, David A. [1 ,2 ,3 ]
Goldberg, Lee R. [1 ,2 ]
Russell, Louise B. [1 ,2 ]
Norton, Laurie A. [1 ,2 ]
Iannotte, Lauren G. [1 ,2 ]
Troxel, Andrea B. [4 ]
机构
[1] Univ Penn, Perelman Sch Med, Dept Med, Philadelphia, PA 19104 USA
[2] Univ Penn, Perelman Sch Med, Dept Hlth Policy & Med Eth, Philadelphia, PA 19104 USA
[3] Corporal Michael J Crescenz VA Med Ctr, Philadelphia, PA USA
[4] NYU, Sch Med, Dept Populat Hlth, Div Biostat, New York, NY USA
来源
关键词
disease management; health care cost; heart failure; morbidity; mortality; HEALTH; HOSPITALIZATION; MANAGEMENT; ADHERENCE; OUTCOMES; RISK; MORTALITY; PATTERNS; SURVIVAL; MODEL;
D O I
10.1161/CIRCOUTCOMES.118.005126
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
BACKGROUND: Congestive heart failure is a major cause of morbidity, mortality, and cost. Disease management programs have shown promise but lack firm evidence of effectiveness and scalability. We describe the motivation, design, and planned analyses of EMPOWER (Electronic Monitoring of Patients Offers Ways to Enhance Recovery), a randomized clinical trial of an innovative intervention incorporating behavioral economic principles with remote monitoring technology embedded within a healthcare system. METHODS AND RESULTS: EMPOWER is an ongoing, pragmatic, randomized clinical trial comparing usual care to an automated hovering intervention that includes patient-level incentives for daily weight monitoring and diuretic adherence combined with automated feedback into the clinical care pathway, enabling real-time response to concerning clinical symptoms. Identification of eligible patients began in May 2016, and implementation of the intervention is feasible. Trial processes are embedded into existing clinical pathways. The primary outcome is time to readmission for any cause. Cost-effectiveness analyses are planned to evaluate the healthcare costs and health outcomes of the approach. CONCLUSIONS: The EMPOWER trial incorporates leading-edge approaches in human motivation, derived from behavioral economics, with contemporary technology to provide scale and exception handling at low cost. The trial is also implemented within the naturalized environment of a health system, as much as possible taking advantage of the existing journeys of patients and workflows of clinicians. A goal of this pragmatic design is to limit resource utilization and also to test an intervention that would need minimal modification to be translated from research into a new way of practice.
引用
收藏
页数:8
相关论文
共 50 条
  • [41] Personalized treatments for depressive symptoms in patients with advanced heart failure: A pragmatic randomized controlled trial
    IsHak, Waguih William
    Korouri, Samuel
    Darwish, Tarneem
    Vanle, Brigitte
    Dang, Jonathan
    Edwards, Gabriel
    Black, Jeanne T.
    Aronow, Harriet
    Kimchi, Asher
    Spiegel, Brennan
    Hedrick, Rebecca
    Chernoff, Robert
    Diniz, Marcio A.
    Mirocha, James
    Manoukian, Vicki
    Harold, John
    Ong, Michael K.
    Wells, Kenneth
    Hamilton, Michele
    Danovitch, Itai
    PLOS ONE, 2021, 16 (01):
  • [42] The Heart Failure Adherence and Retention Trial (HART): Design and rationale
    Powell, Lynda H.
    Calvin, James E.
    de Leon, Carlos F. Mendes
    Richardson, Dejuran
    Grady, Kathleen I.
    Flynn, Kristin J.
    Rucker-Whitaker, Cheryl S.
    Janssen, Imke
    Kravitz, Glenda
    Eaton, Claudia
    AMERICAN HEART JOURNAL, 2008, 156 (03) : 452 - 460
  • [43] Management of elderly patients with congestive heart failure - Design of the trial of intensified versus standard medical therapy in elderly patients with congestive heart failure (TIME-CHF)
    Brunner-La Rocca, Hans Peter
    Buser, Peter Theo
    Schindler, Ruth
    Bernheim, Alain
    Rickenbacher, Peter
    Pfisterer, Matthias
    AMERICAN HEART JOURNAL, 2006, 151 (05) : 949 - 955
  • [44] Rationale and design of the Valsartan Heart Failure Trial: A large multinational trial to assess the effects of valsartan, an angiotensin-receptor blocker, on morbidity and mortality in chronic congestive heart failure
    Cohn, JN
    Tognoni, G
    Glazer, RD
    Spormann, D
    Hester, A
    JOURNAL OF CARDIAC FAILURE, 1999, 5 (02) : 155 - 160
  • [45] Rationale and design of a randomized double-blind trial to study the benefit of colchicine in patients with acutely decompensated heart failure: COLICA trial.
    Fernandez Villa, Noelia
    Perez-Martinez, M. T.
    Garcia-Garcia, A. M.
    Nunez-Villota, J.
    Gonzalez-Juanatey, J. R.
    Taibo-Urquia, M.
    Delgado-Jimenez, J.
    Bayes-Genis, A.
    Llacer-Iborra, P.
    Mirabet-Perez, S.
    Martinez-Selles, M.
    Anguita-Sanchez, M.
    Aimo, A.
    Sanchez-Fernandez, P. L.
    Pascual-Figal, D. A.
    EUROPEAN JOURNAL OF HEART FAILURE, 2024, 26 : 405 - 405
  • [46] Rationale for the Use of Aldosterone Antagonists in Congestive Heart Failure
    Ricardo Rocha
    Gordon H. Williams
    Drugs, 2002, 62 : 723 - 731
  • [47] Rationale for the use of aldosterone antagonists in congestive heart failure
    Rocha, R
    Williams, GH
    DRUGS, 2002, 62 (05) : 723 - 731
  • [48] Rationale for angiotensin receptor blockers in congestive heart failure
    Gradman, AH
    AMERICAN JOURNAL OF MANAGED CARE, 1998, 4 (07): : S405 - S408
  • [49] Rationale and design of the IRON-HF study: A randomized trial to assess the effects of iron supplementation in heart failure patients with anemia
    Beck-Da-Silva, Luis
    Rohde, Luis Eduardo
    Pereira-Barretto, Antonio Carlos
    De Albuquerque, Denilson
    Bocchi, Edimar
    Vilas-Boas, Fabio
    Moura, Lidia Zytynzki
    Montera, Marcelo W.
    Rassi, Salvador
    Clausell, Nadine
    JOURNAL OF CARDIAC FAILURE, 2007, 13 (01) : 14 - 17
  • [50] Multidisciplinary rehabilitation program in recently hospitalized patients with heart failure and preserved ejection fraction: Rationale and design of a randomized controlled trial
    Koifman, Edward
    Grossman, Ehud
    Elis, Avishay
    Dicker, Dror
    Koifman, Bella
    Mosseri, Morris
    Kuperstein, Rafael
    Goldenberg, Ilan
    Kamerman, Tamir
    Levine-Tiefenbrun, Nava
    Klempfner, Robert
    AMERICAN HEART JOURNAL, 2014, 168 (06) : 830 - +